Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy

Abstract Background Aptamer has been called “chemical antibody” which displays the specific affinity to target molecules compared to that of antibodies and possesses several therapeutic advantages over antibodies in terms of size, accessibility to synthesis, and modification. Based on the attractive...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Do-Hun Kim, Jin-Myung Seo, Kyung-Ju Shin, Su-Geun Yang
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Aptamers Aptamer drug conjugates (ApDCs) Cancer therapy Targeted treatment Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/88acda4cac79433d82657ecc3b6c7ea6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:88acda4cac79433d82657ecc3b6c7ea6
record_format	dspace
spelling	oai:doaj.org-article:88acda4cac79433d82657ecc3b6c7ea62021-11-28T12:06:13ZDesign and clinical developments of aptamer-drug conjugates for targeted cancer therapy10.1186/s40824-021-00244-42055-7124https://doaj.org/article/88acda4cac79433d82657ecc3b6c7ea62021-11-01T00:00:00Zhttps://doi.org/10.1186/s40824-021-00244-4https://doaj.org/toc/2055-7124Abstract Background Aptamer has been called “chemical antibody” which displays the specific affinity to target molecules compared to that of antibodies and possesses several therapeutic advantages over antibodies in terms of size, accessibility to synthesis, and modification. Based on the attractive properties, aptamers have been interested in many directions and now are emerged as new target-designed cancer drug. Main body Currently, new types of aptamers have been reported and attracted many scientists’ interesting. Due to simplicity of chemical modification and ready-made molecular engineering, scientists have developed newly designed aptamers conjugated with a wide range of therapeutics, aptamer-drug conjugates; ApDCs, from chemotherapy to phototherapy, gene therapy, and vaccines. ApDCs display synergistic therapeutic effects in cancer treatment. Conclusion In this paper, we reviewed various kinds of ApDCs, i.e., ApDC nucleotide analogs, ApDC by drug intercalation, and ApDC by using chemical linker. Current data prove these ApDCs have sufficient potential to complete clinical development soon. Advanced technology of cancer drug delivery and combination treatment of cancers enables aptamer and conjugated drug (ApDCs) efficient means for targeted cancer treatment that reduces potential toxicity and increases therapeutic efficacy.Do-Hun KimJin-Myung SeoKyung-Ju ShinSu-Geun YangBMCarticleAptamersAptamer drug conjugates (ApDCs)Cancer therapyTargeted treatmentMedical technologyR855-855.5ENBiomaterials Research, Vol 25, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Aptamers Aptamer drug conjugates (ApDCs) Cancer therapy Targeted treatment Medical technology R855-855.5
spellingShingle	Aptamers Aptamer drug conjugates (ApDCs) Cancer therapy Targeted treatment Medical technology R855-855.5 Do-Hun Kim Jin-Myung Seo Kyung-Ju Shin Su-Geun Yang Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy
description	Abstract Background Aptamer has been called “chemical antibody” which displays the specific affinity to target molecules compared to that of antibodies and possesses several therapeutic advantages over antibodies in terms of size, accessibility to synthesis, and modification. Based on the attractive properties, aptamers have been interested in many directions and now are emerged as new target-designed cancer drug. Main body Currently, new types of aptamers have been reported and attracted many scientists’ interesting. Due to simplicity of chemical modification and ready-made molecular engineering, scientists have developed newly designed aptamers conjugated with a wide range of therapeutics, aptamer-drug conjugates; ApDCs, from chemotherapy to phototherapy, gene therapy, and vaccines. ApDCs display synergistic therapeutic effects in cancer treatment. Conclusion In this paper, we reviewed various kinds of ApDCs, i.e., ApDC nucleotide analogs, ApDC by drug intercalation, and ApDC by using chemical linker. Current data prove these ApDCs have sufficient potential to complete clinical development soon. Advanced technology of cancer drug delivery and combination treatment of cancers enables aptamer and conjugated drug (ApDCs) efficient means for targeted cancer treatment that reduces potential toxicity and increases therapeutic efficacy.
format	article
author	Do-Hun Kim Jin-Myung Seo Kyung-Ju Shin Su-Geun Yang
author_facet	Do-Hun Kim Jin-Myung Seo Kyung-Ju Shin Su-Geun Yang
author_sort	Do-Hun Kim
title	Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy
title_short	Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy
title_full	Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy
title_fullStr	Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy
title_full_unstemmed	Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy
title_sort	design and clinical developments of aptamer-drug conjugates for targeted cancer therapy
publisher	BMC
publishDate	2021
url	https://doaj.org/article/88acda4cac79433d82657ecc3b6c7ea6
work_keys_str_mv	AT dohunkim designandclinicaldevelopmentsofaptamerdrugconjugatesfortargetedcancertherapy AT jinmyungseo designandclinicaldevelopmentsofaptamerdrugconjugatesfortargetedcancertherapy AT kyungjushin designandclinicaldevelopmentsofaptamerdrugconjugatesfortargetedcancertherapy AT sugeunyang designandclinicaldevelopmentsofaptamerdrugconjugatesfortargetedcancertherapy
_version_	1718408209732993024

Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy

Ejemplares similares